{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-2857"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-2857","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Increasing the efficacy of Actinomycin D with Resveratrol in Aerodigestive tract cancers","abstract":"Chemotherapy poses a significant challenge for cancer patients due to drug-associated toxicity, which often results from their effects on both healthy (normal) and cancerous cells. While various options aim to reduce toxicity and optimize beneficial effects, a comprehensive solution remains elusive. Cyclotherapy is one such approach developed to protect normal cells from the toxic effects of chemotherapy drugs. The basic principle underlying cyclotherapy is p53- dependent cell cycle arrest of normal cells while killing cancer cells via a p53-independent mechanism using a second drug. In our research, we investigated the inhibitory effects of a combination of two low-dose anticancer drugs, Actinomycin D and Resveratrol, in Aerodigestive tract cancers, which are a leading cause of cancer-related deaths in the United States and globally. p21 plays the central role in p53-dependent cell cycle arrest. Utilizing an advanced technique, digital droplet polymerase chain reaction, we observed a synergistic increase in the expression of p21 mRNA when Actinomycin D and Resveratrol were used in combination. Furthermore, we elucidated the mechanism of cell death induced by the combination of Actinomycin D and Resveratrol by identifying proteins such as p53, PUMA, ATF3, and GDF15. These findings offer valuable insights for the development of future chemotherapeutic combinations involving Actinomycin D and Resveratrol, with the potential to improve cancer management.","abstract_html":"Chemotherapy poses a significant challenge for cancer patients due to drug-associated toxicity, which often results from their effects on both healthy (normal) and cancerous cells. While various options aim to reduce toxicity and optimize beneficial effects, a comprehensive solution remains elusive. Cyclotherapy is one such approach developed to protect normal cells from the toxic effects of chemotherapy drugs. The basic principle underlying cyclotherapy is p53- dependent cell cycle arrest of normal cells while killing cancer cells via a p53-independent mechanism using a second drug. In our research, we investigated the inhibitory effects of a combination of two low-dose anticancer drugs, Actinomycin D and Resveratrol, in Aerodigestive tract cancers, which are a leading cause of cancer-related deaths in the United States and globally. p21 plays the central role in p53-dependent cell cycle arrest. Utilizing an advanced technique, digital droplet polymerase chain reaction, we observed a synergistic increase in the expression of p21 mRNA when Actinomycin D and Resveratrol were used in combination. Furthermore, we elucidated the mechanism of cell death induced by the combination of Actinomycin D and Resveratrol by identifying proteins such as p53, PUMA, ATF3, and GDF15. These findings offer valuable insights for the development of future chemotherapeutic combinations involving Actinomycin D and Resveratrol, with the potential to improve cancer management.","abstract_has_math":false,"creators":["Raji, Lukmon Morenikeji"],"institution":null,"degree_name":"Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"School of Pharmacy","degree_department":null,"school":null,"contributors":["Dr. A.R.M.Ruhul Amin, CommitteeChairperson","Dr. Melinda Varney","Dr.Jeremy McAleer"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:10Z","subjects":["Medical Specialties","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Oncology","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences","chemotherapy","drug-associated toxicity","cyclotherapy","Actinomycin D","Resveratrol","Aerodigestive tract cancers"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/1852","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/1852","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-2857","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. A.R.M.Ruhul Amin, CommitteeChairperson","Dr. Melinda Varney","Dr.Jeremy McAleer"]},{"key":"dc:creator","label":"Author","values":["Raji, Lukmon Morenikeji"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2024-04-30T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2024-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["School of Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medical Specialties","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Oncology","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences","chemotherapy","drug-associated toxicity","cyclotherapy","Actinomycin D","Resveratrol","Aerodigestive tract cancers"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/1852"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Chemotherapy poses a significant challenge for cancer patients due to drug-associated toxicity, which often results from their effects on both healthy (normal) and cancerous cells. While various options aim to reduce toxicity and optimize beneficial effects, a comprehensive solution remains elusive. Cyclotherapy is one such approach developed to protect normal cells from the toxic effects of chemotherapy drugs. The basic principle underlying cyclotherapy is p53- dependent cell cycle arrest of normal cells while killing cancer cells via a p53-independent mechanism using a second drug. In our research, we investigated the inhibitory effects of a combination of two low-dose anticancer drugs, Actinomycin D and Resveratrol, in Aerodigestive tract cancers, which are a leading cause of cancer-related deaths in the United States and globally. p21 plays the central role in p53-dependent cell cycle arrest. Utilizing an advanced technique, digital droplet polymerase chain reaction, we observed a synergistic increase in the expression of p21 mRNA when Actinomycin D and Resveratrol were used in combination. Furthermore, we elucidated the mechanism of cell death induced by the combination of Actinomycin D and Resveratrol by identifying proteins such as p53, PUMA, ATF3, and GDF15. These findings offer valuable insights for the development of future chemotherapeutic combinations involving Actinomycin D and Resveratrol, with the potential to improve cancer management."]},{"key":"dc:title","label":"Title","values":["Increasing the efficacy of Actinomycin D with Resveratrol in Aerodigestive tract cancers"]}]}],"canonical_facts":{"dc:contributor":["Dr. A.R.M.Ruhul Amin, CommitteeChairperson","Dr. Melinda Varney","Dr.Jeremy McAleer"],"dc:creator":["Raji, Lukmon Morenikeji"],"dc:date.available":["2024-04-30T07:00:00Z"],"dc:date.created":["2024-01-01T08:00:00Z"],"dc:description.abstract":["Chemotherapy poses a significant challenge for cancer patients due to drug-associated toxicity, which often results from their effects on both healthy (normal) and cancerous cells. While various options aim to reduce toxicity and optimize beneficial effects, a comprehensive solution remains elusive. Cyclotherapy is one such approach developed to protect normal cells from the toxic effects of chemotherapy drugs. The basic principle underlying cyclotherapy is p53- dependent cell cycle arrest of normal cells while killing cancer cells via a p53-independent mechanism using a second drug. In our research, we investigated the inhibitory effects of a combination of two low-dose anticancer drugs, Actinomycin D and Resveratrol, in Aerodigestive tract cancers, which are a leading cause of cancer-related deaths in the United States and globally. p21 plays the central role in p53-dependent cell cycle arrest. Utilizing an advanced technique, digital droplet polymerase chain reaction, we observed a synergistic increase in the expression of p21 mRNA when Actinomycin D and Resveratrol were used in combination. Furthermore, we elucidated the mechanism of cell death induced by the combination of Actinomycin D and Resveratrol by identifying proteins such as p53, PUMA, ATF3, and GDF15. These findings offer valuable insights for the development of future chemotherapeutic combinations involving Actinomycin D and Resveratrol, with the potential to improve cancer management."],"dc:identifier":["https://mds.marshall.edu/etd/1852"],"dc:subject":["Medical Specialties","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Oncology","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences","chemotherapy","drug-associated toxicity","cyclotherapy","Actinomycin D","Resveratrol","Aerodigestive tract cancers"],"dc:title":["Increasing the efficacy of Actinomycin D with Resveratrol in Aerodigestive tract cancers"],"thesis:degree_discipline":["School of Pharmacy"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Pharmaceutical Sciences"]},"updated_at":"2026-11-21T19:58:10Z"}